Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its just been a long time coming, thought there was a chance we wouldn't get here.
All bets are off now, hundreds of thousands to millions now..............
This is freaking me out a little.
The breakout board has more green than I have seen in a long time, amazing.
Ride the wave
WRONG...................
Just google MM signals
There are lots of them
https://twitter.com/CRDChirp/status/1356595767893491713/photo/1
This is OCTX that seems to have endless shares to dump.
A bit complicated but I think this is what UGA/SBFM are working on.
Discussion and Conclusions
The outbreak of the current coronavirus pandemic leading to COVID-19 disease has
dramatically accelerated research into effective drugs and a vaccine to treat this disease. The
genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) consists of 29811
nucleotides that encode 29 proteins, two of which are proteases. The first of these, SARS-CoV2-Mpro is used by the virus in the process of protein maturation. Its structure has already been
described recently [27]. The results of retargeting about 12,000 drugs and other leading
structures resulted in selection of several candidates for further studies [28]. To date, there is
no information about the activity of the second protease, namely SARS-CoV-2-PLpro. We were
hypothesizing that this enzyme, similarly to SARS-CoV-PLpro, in addition to participating in
the process of virus protein maturation, also performs an additional function, which is to help
the virus in evasion of the host innate immune responses by controlling the deubiquitination
and deISGylation process. Thus, SARS-CoV-2-PLpro is also an excellent candidate for a drug,
not only blocking virus replication, but also inhibiting the dysregulation of signaling cascades
in infected cells [9]. Knowledge of substrate preferences is equally important with
understanding the structure of the protein, as it enables rational design of inhibitors or research
on drug retargeting.
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.068890; this version posted April 29, 2020. The copyright holder for this preprint
Figure 5. Sequence alignment of the PLpro from SARS and SARS2 (Covid19) were
determined using default ClustalX parameters. Secondary structure was shown above sequence
according to PDB 5E6J. Conserved residues are shown as dots. Catalytic cysteines were labeled
with a yellow star. Residues involved in contacts with S1 Ubiquitin residue 73-76 are shaded
yellow. Residues involved in contacts with S1 Ubiquitin residue 1-72 are boxed in purple line.
Residues involved in contacts with S2 Ubiquitin are boxed in blue line.
In our research, we decided to examine the SARS-CoV-2-PLpro substrate preferences
at positions P4-P2 and compare them directly with the well-known SARS virus 2002/03 protein,
SARS-CoV-PLpro. For this purpose, we used positional scanning technology using natural and
unnatural amino acids (HyCoSuL). Library screening revealed that both enzymes recognize
only Gly in P2 and possess broad in P3 and rather narrow substrate specificity at the P4 position.
Moreover, direct analysis of the preferences of both enzymes demonstrate that the architecture
of S4-S2 pockets is almost identical, because they recognize natural and unnatural amino acids
practically in a very similar way. The differences in activity for a given amino acid between the
two enzymes observed in some positions are very small, and there are no amino acids that are
recognized by one enzyme only. This is also confirmed by the analysis of amino acids building
S4-S2 pockets in both enzymes, which is identical (Figure 5). This is critically important
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.068890; this version posted April 29, 2020. The copyright holder for this preprint
information in the aspect of using information from research on inhibitors or retargeting of
drugs conducted in the past for SARS-CoV-PLpro for immediate application to SARS-CoV-2-
PLpro. Analysis of kinetic parameters for tetrapeptide substrates for both enzymes shows a high
degree of similarity in terms of kcat/Km values, proving that the catalytic yields of both enzymes
are also similar. Importantly, the sequences containing unnatural amino acids at P4-P3 positions
were recognized only by both SARS-PLpro, not MERS-PLpro and human UCH-L3. Thus, in
the next step we developed covalent inhibitors based on two selected substrate sequences. These
inhibitors proved to be active and selectively inhibited of the SARS-PLpro, but much weaker
for MERS-PLpro and practically ineffective for human UCH-L3. This is excellent information
in terms of conducting research towards the search for peptide antiviral compounds targeted to
this enzyme. In our research, we also decided to check whether SARS-CoV-2-PLpro has the
ability to bind ubiquitin. Analysis of the enzyme kinetics of the Ub-ACC substrate indicates
that it is efficiently processed by the enzyme, but the difference between the tetrapeptide
substrate and ubiquitin is only about ten times, when in the case of SARS-CoV-PLpro this
difference is around sixty times (Table 1). This indicates some differences between both
enzymes in the aspect of interaction in the exosite binding region (Figure 5) related to amino
acids identity and similarity. A similar observation also resulted from a study in which we used
the Biotin-Ub-VME inhibitor. Both enzymes are effectively inhibited, however SARS-CoVPLpro with slightly higher efficiency.
In summary, our research shows a very high level of similarity between the two enzymes
in terms of substrate specificity near the binding pocket, which can immediately be used to
search for effective antiviral molecules, in silico drug search as well as retargeting of known
drugs. Our data also gives a hope for design of a drug that can act as a pan-selective inhibitor
against both SARS-CoV-PLpro and SARS-CoV-2-PLpro, and may have some universal value
against emerging coronaviruses in the near future.
Look at number 23 on the breakout board, about to move
I'm going to head over in Roytoy 2
Who is going to attend the ceremony when the good doctor gets the peace prize??????
Time magazine "Man of the year".
SBFM-pl4 may be just as effective on the Flu, what is that market worth today?
WRONG
Vaccines are not available
They do not work 110 percent
lots of people won't take them.
The vaccine for the flu has been around forever but is still only 60 percent effective and only 60 percent of people take it.
You should update Stevie Wonder
Slapping the ask,all day long
That's because it is true.
Lots of MM signals to keep this down....
Good luck
I think what UGA was working on may reach into the Patent protected methodology that SBFM owns.
They had to share or we could sue later....Maybe
IMO
In the last 6 business days there has been 3 PR's
Show me another ticker that has done this with honest news and not just pump info.
They have made progress, read the PR again, they have completed in vitro studies obviously with success as they want to do more testing for all 3 compounds.
Maybe a mix of the 3 will be needed to make the pill even better.
Are you kidding me............
Do you understand the implications of the news today?????
Progress is being made in an amazing way, why not be happy with that.
I was thinking of changing the name of my current boat to Roytoy but looks like it will be more appropriate to name my new one Roytoy2 as Roytoy has already been taken.
The next big news will raise the question of where to keep my new boat, here in Canada or at my new place in a warmer climate.
SBFM sure is causing me to have problems making the right decisions....
How big of a boat.....
How big should the Roytoy letters be on the back
What country to buy a new place
What marina to put Roytoy
Oh the decisions.........
Seem to be shorting anywhere from 30% to 75% of the daily volume.
What we don't make today, we will make tomorrow or the next day.
Then one day in the near future, the payoff will be astounding.
I think I'm ready for a few more sticks.....
I'm laughing now....
There is always someone out there that needs beer money for the weekend.
MM's taking it down to load.
I've been here with many others since trips.
You will have to go back in time for that.
And that is during the holiday season, maybe sooner.
Either way ,nobody has anything close to the potential we have with SBFM-
PL4. Other companies are working on Covid so is SBFM but there are also lots of other potentials for this drug (Hepatitis and a huge list of others)
We will be rewarded for the Covid cure and after lots of other applications will be tested and approved no doubt.
Bottom line, the next 3 to 6 months will make us all think about early retirement early.
UGA stated working on this stuff during the Sars outbreak, so yes they are leaders in the viruses and testing for them, however the latest patent applied for process is new to their current testing format hence the partnership with SBFM.
We are mixing the older research with ground breaking approaches to eliminating the ability of the virus to replicate. The old process tried to kill the virus, two different paths completely.
Why must there be a connection, why guess.
Life is better when you talk about facts.
Lots of people on this board forecast EOD prices and timeframes that are simply a guess.
Proper DD is based on facts not wishes.
The volunteers for the covid study has nothing to do with SBFM.
Read about the study, it is to see how long antibodies stay in the body after getting Covid and after being vaccinated.
This is a fact and is what I'm referring to.
It does not have anything to do with SBFM.
Nothing
It does not have anything to do with SBFM.
Nothing
You mean hundreds of thousands of dollars
It goes up 3.88
Simple
You forgot.
SONIC BOOM imminent.............
Why would you say 18 to 24 months.
Don't talk to me weirdo
I'm not interested in you opinion, I'm an intelligent person who does not need your input.
Bottom line, I've made hundreds of thousands of dollars here and will continue to make more without your input or help.
Thanks for wasting our time, go home
You did not base your comments on human trials you stated a 4 step process.
You are wrong